“2022 Guidelines At-A-Glance, Prostate Edition” booklets available exclusively at Exact Sciences’ AUA2022 Booth (#647) in New Orleans, May 12-16
Exact Sciences Corp., a global leader in advanced cancer diagnostics, today announced the American Urological Association (AUA) updated their guidelines to include genomic assays, such as the Oncotype DX Genomic Prostate Score® (GPS™) test, when treating men with localized prostate cancer. The 2022 guidelines now state that clinicians may selectively use tissue-based genomic biomarkers when added risk-stratification may alter clinical decision-making. Exact Sciences will exclusively offer the at-a-glance booklets of the prostate cancer guidelines and exhibit its full portfolio of prostate cancer genomic tests at booth #647 during the AUA 2022 Annual Meeting from May 12-16 in New Orleans. This is the first in-person AUA meeting where Exact Sciences will feature its full Oncotype® portfolio of urologic genomic assays, including the Oncotype DX® GPS test for localized prostate cancer; the Oncotype MAP™ Pan-Cancer Tissue test for solid tumors, including advanced prostate cancer; and the Oncotype DX AR-V7 Nucleus Detect® test for metastatic castration-resistant prostate cancer.
“We’re pleased that the updated guidelines recognize the impact genomic assays can have on treatment decision making for men with localized prostate cancer,” said Daniel Shoskes, MD, MSc, FRCS(C), Medical Director of Urologic Oncology Medical Affairs at Exact Sciences and Emeritus Professor of Urology at The Cleveland Clinic. “While every patient is unique, clinical guidelines can help physicians offer the best evidence-based care using the most current data. The Oncotype DX GPS test is one of the most rigorously studied assays in localized prostate cancer patients, helping physicians refine risk stratification and make decisions between active surveillance and definitive treatment in low-risk patients, and to determine treatment intensity in higher-risk patients.”
Key AUA activities featuring the Oncotype portfolio during the meeting include:
Thursday, May 12: Advanced Prostate Cancer: Practical Considerations for Incorporating Genomic Profiling in Practice
Topic: Learn How Genomic Profiling Can Help Guide Therapy Selection for Advanced Prostate Cancer
Presenter: Gautam Jayram, MD
Co-director, Advanced Therapeutic Center Urology Associates, PC
Time: 11:45 AM – 1:00 PM CT
Location: Room 267, Hilton New Orleans Riverside
Friday, May 13: Industry Clinical Update Theater #1043
Topic: A Case Based Discussion: Individualizing Localized Prostate Cancer Treatment Decisions with the Oncotype DX® GPS™ Assay
Presenters: Stephen Canfield, MD
Chief of Urology / Memorial Hermann-Texas Medical Center / McGuire Distinguished Chair in Urology / McGovern Medical School at UTHealth
Edward Uchio, MD
Jerry D. Choate Chair in Urologic Oncology / Director of Clinical Research / Professor, Department of Urology / University of California, Irvine
Daniel Shoskes, MD, MSc, FRCS(C)
Medical Director, Urologic Oncology Medical Affairs, Exact Sciences / Emeritus Professor of Urology, The Cleveland Clinic
Time: 9:30 – 10:30 AM CT
Location: Booth #647
Sunday, May 15: Urologic Society for American Veterans Presentation
Topic: Performance of the Oncotype DX Genomic Prostate Score® Test in African American Patients with Localized Prostate Cancer
Presenter: Daniel Shoskes, MD, MSc, FRCS(C)
Medical Director, Urologic Oncology Affairs at Exact Sciences / Emeritus Professor of Urology, The Cleveland Clinic
Time: 12:50 – 1:10 PM CT
Location: St. Charles Ballroom, Hilton New Orleans Riverside
In addition to the above presentations, Exact Sciences is hosting an Advocacy Roundtable on Sunday, May 15 from 7:00 – 8:30 AM CT. Leading prostate cancer and pan-cancer patient advocacy groups are invited to hear the latest updates on Exact Sciences’ prostate cancer genomic tests and to learn more about the company.
For more information about Exact Sciences’ AUA events and programming, visit https://www.oncotypeiq.com/en-US/announcements/AUA
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
